Cargando…
A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis
Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimu...
Autores principales: | Lyles, Laine, Farmer, Reagan, Abougergi, Marwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519460/ https://www.ncbi.nlm.nih.gov/pubmed/37753105 http://dx.doi.org/10.14309/crj.0000000000001162 |
Ejemplares similares
-
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020) -
Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab
por: Donnelly, Jonathan P., et al.
Publicado: (2021) -
A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab
por: Bloomer, Chance H., et al.
Publicado: (2022) -
Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022) -
Subcutaneous Tocilizumab May Be Effective in Refractory Fibromyalgia Patients
por: Tang, Kuo-Tung, et al.
Publicado: (2023)